Lenvatinib Plus Pembrolizumab Tops Sunitinib in Advanced RCC
FRIDAY, Feb. 19, 2021 -- For first-line treatment of advanced renal cell carcinoma, progression-free and overall survival are significantly longer with lenvatinib plus pembrolizumab versus sunitinib, according to a study published online Feb. 13 in...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Carcinoma | Kidney Cancer | Pharmaceuticals | Renal Cell Carcinoma | Study